Sitio Web del Instituto Nacional del Cáncer. El análisis del antígeno prostático específico (PSA): preguntas y respuestas. «Enllaç». Arxivat de l'original el 2007-10-11. [Consulta: 13 juliol 2008].
Error: hi ha títol o url, però calen tots dos paràmetres.Chuang AY, Demarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. «[{{{url}}} Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma]» p. 1246-1255, 2007. DOI: 10.1097/PAS.0b013e31802f5d33.
«Human PubMed Reference:». National Center for Biotechnology Information, U.S. National Library of Medicine.
«Mouse PubMed Reference:». National Center for Biotechnology Information, U.S. National Library of Medicine.
Lilja H. «Biology of Prostate-Specific Antigen». Urology, 62, (5 Suppl 1), Nov 2003, pàg. 27-33. PMID: 14607215 [Consulta: 17 setembre 2006].
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr «Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter». N Engl J Med, 350, 22, maig 27, 2004, pàg. 2239-46. PMID: 15163773.
Carter HB «Prostate cancers in men with low PSA levels--must we find them?». N Engl J Med, 350, 22, maig 27, 2004, pàg. 2292-4. PMID: 15163780.
Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL «Measurement of prostate-specific antigen in serum as a screening test for prostate cancer». N Engl J Med, 324, 17, abril 25, 1991, pàg. 1156-61. PMID: 1707140.
Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. «Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men». J Urol, 151, 5, maig 1994, pàg. 1283-90. PMID: 7512659.
Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A, Richie J, deKernion J, Walsh P, Scardino P, Lange P, Subong E, Parson R, Gasior G, Loveland K, Southwick P «Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.». JAMA, 279, 19, 1998, pàg. 1542-7. PMID: 9605898.
Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H, Minasian L, Ford L, Lippman S, Crawford E, Crowley J, Coltman C «Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.». N Engl J Med, 350, 22, 2004, pàg. 2239-46. PMID: 15163773.
Catalona W, Smith D, Ornstein D «Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.». JAMA, 277, 18, 1997, pàg. 1452-5. PMID: 9145717.
Carter H, Pearson J, Metter E, Brant L, Chan D, Andres R, Fozard J, Walsh P «Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.». JAMA, 267, 16, 1992, pàg. 2215-20. PMID: 1372942.
D'Amico A, Chen M, Roehl K, Catalona W «Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.». N Engl J Med, 351, 2, 2004, pàg. 125-35. PMID: 15247353.
Sitio Web del Instituto Nacional del Cáncer. El análisis del antígeno prostático específico (PSA): preguntas y respuestas. «Enllaç». Arxivat de l'original el 2007-10-11. [Consulta: 13 juliol 2008].